CAT-2054: Phase IIa started

Catabasis began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate 250 and 400 mg oral CAT-2054 once or twice daily with 40 mg oral atorvastatin daily for 4 weeks in about 150 patien...